Posted by Michael Wonder on 24 Oct 2016
aTyr Pharma receives FDA fast track designation for Resolaris to treat facioscapulohumeral muscular dystrophy
24 October 2016 - aTyr Pharma today announced that its product candidate Resolaris was granted fast track designation by the US FDA for the treatment of facioscapulohumeral muscular dystrophy (FSHD), making it the first known therapeutic candidate for the treatment of patients with FSHD to receive the designation.
Resolaris, a designated orphan drug in FSHD, is currently being studied in a Phase 1b/2 clinical program.
